Autor: |
Helene Damhofer, Tülin Tatar, Benjamin Southgate, Scott Scarneo, Karl Agger, Daria Shlyueva, Lene Uhrbom, Gillian M. Morrison, Philip F. Hughes, Timothy Haystead, Steven M. Pollard, Kristian Helin |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Cell Death and Disease, Vol 15, Iss 4, Pp 1-17 (2024) |
Druh dokumentu: |
article |
ISSN: |
2041-4889 |
DOI: |
10.1038/s41419-024-06654-1 |
Popis: |
Abstract Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in a significant fraction of GSCs. Loss of TAK1 kinase activity results in RIPK1-dependent apoptosis via Caspase-8/FADD complex activation, dependent on autocrine TNFα ligand production and constitutive TNFR signaling. We identify a transcriptional signature associated with immune activation and the mesenchymal GBM subtype to be a characteristic of cancer cells sensitive to TAK1 perturbation and employ this signature to accurately predict sensitivity to the TAK1 kinase inhibitor HS-276. In addition, exposure to pro-inflammatory cytokines IFNγ and TNFα can sensitize resistant GSCs to TAK1 inhibition. Our findings reveal dependency on TAK1 kinase activity as a novel vulnerability in immune-activated cancers, including mesenchymal GBMs that can be exploited therapeutically. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|